European Commission approves Pfizer's quto-bead monobiosimilar Trazimera for treatment of stomach cancer
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, the European Commission (EC) has approved trazimera, an anti-biosimilar, for treatment of HER2-positive breast cancer and HER2-positive metastatic stomach cancer or esophageal esophageal adenocarcinoma, the usPharmaceuticalsannouncedabout TrazimeraTrazimera does the brand drug for Roche's Herceptin (Hercetin, generic name: trastuzumab, qutobeu monofight)Herceptin is a heavyweightproductof Roche(with global sales of $7 billion in 2017)Trazimera is expected to provide patients in Europe with a more affordable treatment option that will help address the evolving needs ofmedical(systems, doctors, taxpayers and patients) in Europerelated studiesTrazimera's approval are based on a comprehensive package and overall evidence of a high similarity between the product and the original drug Herceptin, including a comparative result from a clinical study of REFLECTIONS B327-02, which confirmed that two products were clinically equivalent in treating HER2-positive metastatic breast cancer with no clinical differencesas part of the REFLECTIONS clinical program, Trazimera has studied nearly 500 patients in more than 20 countries worldwide to dateTrazimera is Pfizer's fourth biosimilar approved in the European Union and the first approved oncology student genericAt present, a total of nine biosimilars in the Pfizer biosimilar pipeline are in different stages of development
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
